In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function
Authors: William G. Herrington, Doreen Zhu, Richard Haynes
Journal: Annals of Internal Medicine (2019)

ACP Journal Club19 February 2019In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal functionWilliam G. Herrington, MD, Doreen Zhu, MBChB, Richard Haynes, DMWilliam G. Herrington, MDMedical Research Council–Population Health Research Unit, University of Oxford, Oxford, England, UK (W.G.H., D.Z., R.H.)Search for more papers by this author, Doreen Zhu, MBChBMedical Research Council–Population Health Research Unit, University of Oxford, Oxford, England, UK (W.G.H., D.Z., R.H.)Search for more papers by this author, Richard Haynes, DMMedical Research Council–Population Health Research Unit, University of Oxford, Oxford, England, UK (W.G.H., D.Z., R.H.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJ201902190-015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationNeuen BL, Ohkuma T, Neal B, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation. 2018;138:1537-50. https://pubmed.ncbi.nlm.nih.gov/29941478Clinical Impact RatingsGIM/FP/GP: Cardiology: Endocrinology: Nephrology: References1 Wanner C, Inzucchi SE, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323-34. [PMID: 27299675] Google Scholar2 Wiviott SD, Raz I, Bonaca MP, et al; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-57. [PMID: 30415602] Google Scholar3 Cherney DZ, Cooper ME, Tikkanen I, et al. Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018;93:231-44. [PMID: 28860019] Google Scholar4 Jardine MJ, Mahaffey KW, Neal B, et al; CREDENCE study investigators. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol. 2017;46:462-72. [PMID: 29253846] Google Scholar5 Herrington WG, Preiss D, Haynes R, et al. The potential for improving cardio-renal outcomes by sodium–glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J. 2018;11:749-61. Google Scholar Author, Article, and Disclosure InformationAffiliations: Medical Research Council–Population Health Research Unit, University of Oxford, Oxford, England, UK (W.G.H., D.Z., R.H.)This article was published at Annals.org on 5 February 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 19 February 2019Volume 170, Issue 4Page: JC15KeywordsCardiovascular disease riskEstimated glomerular filtration rateHazard ratioMyocardial infarctionRenal diseasesRenal failureStandard deviationSystolic pressureType 2 diabetesVascular diseases ePublished: 19 February 2019 Issue Published: 19 February 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...